Wes Streeting has expressed his emotional struggle when facing parents like Jesy Nelson due to the absence of newborn screening for a severe muscle degenerative illness.
The former member of the music group Little Mix and the Mirror newspaper are advocating for spinal muscular atrophy (SMA) screening to be integrated into the NHS heel prick test. Presently, infants are only diagnosed after irreversible muscle degeneration, often leading to a lifelong reliance on a wheelchair.
Health Secretary Mr. Streeting has raised concerns to the UK National Screening Committee regarding potentially modifying a forthcoming NHS trial to encompass screening all newborns for SMA. Certain regions in England are considering leaving some babies untested to serve as a “control group” for health outcome comparisons.
Speaking to the Mirror, Mr. Streeting acknowledged the complexity of the issue highlighted by Jesy, emphasizing the need for broader screening coverage to prevent other families from enduring similar challenges.
The Mirror is campaigning for the inclusion of a £5 blood test for SMA in the routine NHS heel prick test for all newborns. Currently, there are three NHS-approved treatments that can address the faulty gene or provide necessary protein replacements to prevent muscle deterioration, but they must be administered promptly after birth.
Jesy, informed that her twins may never walk, shared her experience of their delayed diagnosis at six months despite frequent medical consultations. Mr. Streeting is actively reviewing the situation and has pledged to update Jesy, the SMA community, and the Mirror on any progress made.
Untreated infants with SMA can require extensive medical support, including wheelchairs, breathing aids, and tube feeding. The decision to exclude a third of newborns in England from testing for SMA has been criticized as unethical by experts.
While the UK National Screening Committee initially excluded SMA from the newborn screening program in 2018, the availability of effective treatments since 2019 has prompted reconsideration. Although a nationwide screening rollout may not occur before 2031, Scotland has decided to implement SMA screening as part of routine newborn care from the spring.
International evidence supports immediate SMA screening for all newborns, as done in the US and most of Europe. Mr. Streeting reiterated the importance of evidence-based decision-making and expressed his commitment to exploring additional screening opportunities.
SMA patients have a genetic defect affecting nerve cell health, leading to muscle deterioration. Mr. Streeting emphasized his personal dedication to ensuring timely access to diagnosis and treatment for children with SMA, inspired by success stories within his constituency.
Giles Lomax, CEO of SMA UK, commended the health secretary’s commitment to expanding and expediting SMA screening nationwide, emphasizing the urgency of timely intervention for affected children.
